Novartis, Dana-Farber seek to bar generic leukaemia drug

Novartis Pharmaceuticals and the Dana-Farber Cancer Institute have filed two lawsuits to bar generic versions of leukaemia drug, Rydapt (midostaurin).

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Novartis to sell Roche shares back for $20.7 billion

5 November 2021 Novartis yesterday, November 4, announced that it is selling its entire stake in Roche—equating to 53.3 million bearer shares—back to the Swiss healthcare company for the sum of $20.7 billion.

Big Pharma

Novartis' Gilenya patent survives invalidity bid

12 May 2022 Novartis has convinced a Delaware court that a patent for its flagship multiple sclerosis treatment Gilenya is directed at patent-eligible matter, dismissing a challenge from Handa Pharmaceuticals that the patent is directed at natural phenomena and invalid.

Americas

SCOTUS deals fresh blow to Novartis’ MS drug patent

18 April 2023 Petition to review invalidation of Gilenya patent denied | Novartis challenged decision resulting from a change in judicial panel.